Toxicités cutanées et efficacité de l’enfortumab vedotin. Expérience monocentrique en vie réelle
A. Rajkumar(Hôpital Foch), Christine L. Abraham(Hôpital Foch), Y. Neuzillet(Université de Versailles Saint-Quentin-en-Yvelines), Philippe Beuzeboc(Hôpital Foch), C. Lepage(Hôpital Foch), Yanish Soorojebally(Université de Versailles Saint-Quentin-en-Yvelines), Karine Sejean(Hôpital Foch), T. Lebret, Brigitte Bonan(Hôpital Foch)
Cited by 0
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
|Journal of Clinical Oncology|2021|530
Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old
|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2015|227
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
|European Journal of Cancer|2021|174